- Home
- SGLY vs AYTU Comparison
SGLY vs AYTU Comparison
Compare SGLY & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- AYTU
- Stock Information
- Founded
- SGLY 2001
- AYTU N/A
- Country
- SGLY United States
- AYTU United States
- Employees
- SGLY N/A
- AYTU N/A
- Industry
- SGLY
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- AYTU Health Care
- Exchange
- SGLY Nasdaq
- AYTU Nasdaq
- Market Cap
- SGLY 15.9M
- AYTU 15.0M
- IPO Year
- SGLY 2008
- AYTU N/A
- Fundamental
- Price
- SGLY $1.68
- AYTU $2.35
- Analyst Decision
- SGLY
- AYTU
- Analyst Count
- SGLY 0
- AYTU 0
- Target Price
- SGLY N/A
- AYTU N/A
- AVG Volume (30 Days)
- SGLY 191.0K
- AYTU 30.7K
- Earning Date
- SGLY 11-11-2024
- AYTU 11-12-2024
- Dividend Yield
- SGLY N/A
- AYTU N/A
- EPS Growth
- SGLY N/A
- AYTU N/A
- EPS
- SGLY N/A
- AYTU N/A
- Revenue
- SGLY $3,370,424.00
- AYTU $81,002,000.00
- Revenue This Year
- SGLY N/A
- AYTU N/A
- Revenue Next Year
- SGLY N/A
- AYTU N/A
- P/E Ratio
- SGLY N/A
- AYTU N/A
- Revenue Growth
- SGLY N/A
- AYTU N/A
- 52 Week Low
- SGLY $1.27
- AYTU $2.20
- 52 Week High
- SGLY $7.65
- AYTU $3.50
- Technical
- Relative Strength Index (RSI)
- SGLY 42.00
- AYTU 44.78
- Support Level
- SGLY $1.27
- AYTU $2.26
- Resistance Level
- SGLY $1.79
- AYTU $2.44
- Average True Range (ATR)
- SGLY 0.22
- AYTU 0.15
- MACD
- SGLY 0.10
- AYTU -0.01
- Stochastic Oscillator
- SGLY 41.00
- AYTU 15.25
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.